We, the undersigned, urge the FDA and other regulatory bodies to protect patient access to compounded GLP-1 treatments, which have been essential for the health and well-being of hundreds of thousands of Americans.

Due to ongoing affordability and availability challenges, many patients have turned to compounded semaglutide through providers such as Hers as a necessary alternative to costly brand-name medications from Eli Lilly and Novo Nordisk. If the FDA moves forward with restrictions on compounded GLP-1s, countless patients will face the impossible choice of either paying significantly higher prices for brand-name drugs or losing access to a treatment that has been life-changing.

Compounded GLP-1s are not merely an alternative—they are a vital, safe, and effective option for those who depend on them. Restricting their availability would jeopardize the health of patients who have no other viable choices.

We call on policymakers to recognize the real and life-altering impact of these treatments. We urge you to ensure that patients continue to have access to compounded GLP-1s as a critical part of their health management.

Please listen to the voices of those who rely on this medication and take action to protect access to compounded GLP-1 treatments.

Sign this petition to demand continued access to life-saving GLP-1 treatments!